International Assets Investment Management LLC Has $19.17 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

International Assets Investment Management LLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 38,432.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,414 shares of the company’s stock after purchasing an additional 57,265 shares during the quarter. International Assets Investment Management LLC owned 0.19% of Medpace worth $19,165,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. TD Asset Management Inc grew its holdings in shares of Medpace by 22.9% during the 1st quarter. TD Asset Management Inc now owns 574,149 shares of the company’s stock valued at $232,042,000 after purchasing an additional 107,108 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Medpace by 38.3% during the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock valued at $182,692,000 after purchasing an additional 122,800 shares during the last quarter. Epoch Investment Partners Inc. grew its holdings in shares of Medpace by 15.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 406,446 shares of the company’s stock valued at $164,265,000 after purchasing an additional 53,983 shares during the last quarter. Clearbridge Investments LLC grew its holdings in shares of Medpace by 55.1% during the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock valued at $166,343,000 after purchasing an additional 143,481 shares during the last quarter. Finally, Bessemer Group Inc. grew its holdings in shares of Medpace by 1.6% during the 1st quarter. Bessemer Group Inc. now owns 394,834 shares of the company’s stock valued at $159,572,000 after purchasing an additional 6,137 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of research reports. TD Cowen reduced their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Redburn Atlantic initiated coverage on shares of Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 target price on the stock. Guggenheim reduced their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a report on Wednesday, July 24th. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $420.00 to $350.00 in a report on Friday, September 27th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Medpace currently has a consensus rating of “Hold” and an average target price of $380.00.

Medpace Trading Up 0.1 %

Shares of Medpace stock opened at $329.76 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $239.00 and a 12-month high of $459.77. The company has a market cap of $10.22 billion, a price-to-earnings ratio of 33.61, a PEG ratio of 1.74 and a beta of 1.35. The company’s 50-day moving average price is $349.01 and its 200-day moving average price is $380.03.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. During the same period in the prior year, the firm posted $2.22 earnings per share. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 11.77 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.